- Home
- OPAD vs IFRX Comparison
OPAD vs IFRX Comparison
Compare OPAD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- IFRX
- Stock Information
- Founded
- OPAD 2015
- IFRX 2007
- Country
- OPAD United States
- IFRX Germany
- Employees
- OPAD N/A
- IFRX N/A
- Industry
- OPAD Real Estate
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- IFRX Health Care
- Exchange
- OPAD Nasdaq
- IFRX Nasdaq
- Market Cap
- OPAD 89.3M
- IFRX 86.0M
- IPO Year
- OPAD N/A
- IFRX 2017
- Fundamental
- Price
- OPAD $1.83
- IFRX $1.26
- Analyst Decision
- OPAD Hold
- IFRX Strong Buy
- Analyst Count
- OPAD 4
- IFRX 5
- Target Price
- OPAD $2.22
- IFRX $9.80
- AVG Volume (30 Days)
- OPAD 1.8M
- IFRX 7.6M
- Earning Date
- OPAD 11-03-2025
- IFRX 11-07-2025
- Dividend Yield
- OPAD N/A
- IFRX N/A
- EPS Growth
- OPAD N/A
- IFRX N/A
- EPS
- OPAD N/A
- IFRX N/A
- Revenue
- OPAD $627,966,000.00
- IFRX $73,729.00
- Revenue This Year
- OPAD N/A
- IFRX N/A
- Revenue Next Year
- OPAD $31.90
- IFRX $1,216.24
- P/E Ratio
- OPAD N/A
- IFRX N/A
- Revenue Growth
- OPAD N/A
- IFRX N/A
- 52 Week Low
- OPAD $0.91
- IFRX $0.71
- 52 Week High
- OPAD $6.35
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- OPAD 37.80
- IFRX 47.36
- Support Level
- OPAD $1.64
- IFRX $1.25
- Resistance Level
- OPAD $2.19
- IFRX $1.94
- Average True Range (ATR)
- OPAD 0.19
- IFRX 0.19
- MACD
- OPAD 0.02
- IFRX -0.02
- Stochastic Oscillator
- OPAD 29.13
- IFRX 14.74
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.